

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act; and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

This announcement is not a prospectus. Potential investors should read the prospectus dated May 5, 2026 (the “**Prospectus**”) issued by Metis TechBio Co., Ltd. (劑泰科技(北京)股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, CLSA Limited as the stabilizing manager (the “**Stabilizing Manager**”) or any person acting for it may make purchases, over-allocate or effect transactions in the market or otherwise take such stabilizing action(s) with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. Any such stabilizing action will be effected in compliance with all applicable laws and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules under the SFO. However, there is no obligation on the Stabilizing Manager or any person acting for it to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing Manager or any person acting for it, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days after the last day for lodging applications under the Hong Kong Public Offering.

Potential investors should note that no stabilizing action can be taken to support the price of the H Shares for longer than the stabilization period, which will begin on the Listing Date and is expected to expire on June 7, 2026, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to procure subscribers for, or themselves to subscribe for, the Hong Kong Offer Shares, are subject to termination by the Joint Sponsors and the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) if certain grounds arise prior to 8:00 a.m. on the Listing Date. Such grounds are set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus. It is important that you refer to that section for further details.



Metis TechBio Co., Ltd.
劑泰科技(北京)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

Global Offering

Number of Offer Shares under the Global Offering	201,229,000 H Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	10,061,500 H Shares (subject to reallocation)
Number of International Offer Shares	191,167,500 H Shares (subject to reallocation and the Over-allotment Option)
Offer Price	HK\$10.50 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and Accounting and Financial Reporting Council transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	RMB0.10 per H share
Stock code	7666

Joint Sponsors



Overall Coordinators and Joint Global Coordinators



Joint Bookrunners and Joint Lead Managers



APPLICATION FOR LISTING ON THE STOCK EXCHANGE

We have applied to the Stock Exchange for the listing of, and permission to deal in, (i) the H Shares to be issued pursuant to the Global Offering (including any H Shares which may be issued pursuant to the exercise of the Over-allotment Option), (ii) the H Shares to be converted from the Unlisted Shares (as adjusted by the Share Subdivision) and (iii) the additional Shares may be issued under the Employee Incentive Schemes.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Wednesday, May 13, 2026, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, May 13, 2026.

**IMPORTANT NOTICE TO INVESTORS:
FULLY ELECTRONIC APPLICATION PROCESS**

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the prospectus in relation to the Hong Kong Public Offering.

The prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “*HKEXnews > New Listings > New Listing Information*” and our website at www.metistechbio.com. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
White Form eIPO service	www.eipo.com.hk	Investors who would like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Tuesday, May 5, 2026 to 11:30 a.m. on Friday, May 8, 2026 (Hong Kong time). The latest time for completing full payment of application monies will be 12:00 noon on Friday, May 8, 2026 (Hong Kong time).
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit electronic application instruction(s) on your behalf through HKSCC’s FINI system in accordance with your instructions.	Investors who would not like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant’s stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the Prospectus are identical to the Prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.

Please refer to “How to Apply for Hong Kong Offer Shares” for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service or the **HKSCC EIPO** channel must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table below. If you are applying through the **White Form eIPO** service, you may refer to the table below for the amount payable for the number of H Shares you have selected. You must pay the respective maximum amount payable on application in full upon application for Hong Kong Offer Shares. If you are applying through the **HKSCC EIPO** channel, your **broker** or **custodian** may require you to pre-fund your application in such amount as determined by the **broker** or **custodian**, based on the applicable laws and regulations in Hong Kong. You are responsible for complying with any such pre-funding requirement imposed by your broker or custodian with respect to the Hong Kong Offer Shares you applied for.

No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application <i>HK\$</i>
500	5,302.95	6,000	63,635.35	40,000	424,235.70	400,000	4,242,357.00
1,000	10,605.89	7,000	74,241.24	45,000	477,265.17	500,000	5,302,946.26
1,500	15,908.84	8,000	84,847.15	50,000	530,294.63	1,000,000	10,605,892.50
2,000	21,211.79	9,000	95,453.03	60,000	636,353.56	1,500,000	15,908,838.76
2,500	26,514.73	10,000	106,058.93	70,000	742,412.48	2,000,000	21,211,785.00
3,000	31,817.68	15,000	159,088.39	80,000	848,471.40	2,500,000	26,514,731.26
3,500	37,120.63	20,000	212,117.86	90,000	954,530.33	3,000,000	31,817,677.50
4,000	42,423.56	25,000	265,147.31	100,000	1,060,589.26	3,500,000	37,120,623.76
4,500	47,726.52	30,000	318,176.78	200,000	2,121,178.50	4,000,000	42,423,570.00
5,000	53,029.47	35,000	371,206.23	300,000	3,181,767.76	5,030,500 ⁽¹⁾	53,352,942.22

Notes:

- (1) The maximum number of Hong Kong Offer Shares you may apply for.
- (2) The amount payable is inclusive of brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee. If your application is successful, the brokerage will be paid to the Exchange Participants and the SFC transaction levy, the AFRC transaction levy and the Stock Exchange trading fee will be paid to the Stock Exchange (in the case of the SFC transaction levy and the AFRC transaction levy, collected by the Stock Exchange on behalf of the SFC and the AFRC, respectively).

No application for any other number of Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 10,061,500 H Shares (subject to reallocation), representing approximately 5% of the total number of Offer Shares initially available under the Global Offering; and
- the International Offering of initially 191,167,500 H Shares (subject to reallocation and the Over-allotment Option), representing approximately 95% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules (as modified by Rule 18C.09 of the Listing Rules) and Chapter 4.14 of the Guide for New Listing Applicants issued by the Stock Exchange, the Sponsor-Overall Coordinators (for themselves and on behalf of the Underwriters) may, at their sole discretion, reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Chapter 4.14 of the Guide for New Listing Applicants issued by the Stock Exchange, if such reallocation is done other than pursuant to the clawback mechanism as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation and clawback” in the Prospectus, the maximum total number of Offer Shares that may be reallocated to the Hong Kong Public Offering will be 10,061,000 Offer Shares (representing approximately 5.0% of the number of the Offer Shares being offered under the Global Offering), so that the total number of Offer Shares for subscription under the Hong Kong Public Offering will increase up to 20,122,500 H Shares, representing 10.0% of the number of the Offer Shares initially available under the Global Offering.

In connection with the Global Offering, our Company is expected to grant the Over-allotment Option to the International Underwriters, exercisable by the Sponsor-Overall Coordinators (for themselves and on behalf of the International Underwriters) at any time from the Listing Date until 30 days after the last day for lodging applications under the Hong Kong Public Offering, being Sunday, June 7, 2026, to require our Company to issue up to an aggregate of 30,184,000 additional H Shares, representing not more than 15% of the Offer Shares initially available under the Global Offering, at the Offer Price to, among other things, cover over-allocations in the International Offering, if any. If the Over-allotment Option is exercised, an announcement will be made.

PRICING

The Offer Price will be HK\$10.50 per Offer Share, unless otherwise announced by our Company no later than the morning of the last day for lodging applications under the Hong Kong Public Offering, as further explained in the section headed “Structure of the Global Offering – Pricing and Allocation” in the Prospectus. Applicants under the Hong Kong Public Offering may (depending on application channels) be required to pay, on application, the Offer Price of HK\$10.50 per H Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%, amounting to a total of HK\$5,302.95 for one board lot of 500 H Shares.

EXPECTED TIMETABLE⁽¹⁾

Should there be any changes to the dates mentioned in the following expected timetable of the Hong Kong Public Offering, an announcement will be made and published on the website of the Stock Exchange at www.hkexnews.hk and our website at www.metistechbio.com of the revised timetable.

Hong Kong Public Offering commences 9:00 a.m. on Tuesday,
May 5, 2026

Latest time for completing electronic applications under the
White Form eIPO service through the designated
website at www.eipo.com.hk 11:30 a.m. on Friday,
May 8, 2026

Application lists open 11:45 a.m. on Friday,
May 8, 2026

Latest time for (a) completing payment for **White Form eIPO**
applications by effecting internet banking transfer(s) or
PPS payment transfer(s) and (b) giving **electronic application**
instructions to HKSCC. 12:00 noon on Friday,
May 8, 2026

If you are instructing your **broker** or **custodian** who is a HKSCC Participant to apply for Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions, which may be different from the latest time as stated above.

Application lists close 12:00 noon on Friday,
May 8, 2026

Announcement of the level of indications
of interest in the International Offering, the level of
applications in the Hong Kong Public Offering and the basis
of allocation of the Hong Kong Offer Shares to be published
on the website of the Stock Exchange at www.hkexnews.hk
and our website at www.metistechbio.com. no later than 11:00 p.m.
on Tuesday,
May 12, 2026

Results of allocation in the Hong Kong Public Offering to be available through a variety of channels as described in “How to Apply for Hong Kong Offer Shares — B. Publication of Results,” including through:

- (1) the designated results of allocation website at www.iporeresults.com.hk (alternatively: www.eipo.com.hk/eIPOAllotment) with a “search by ID” function from 11:00 p.m. on Tuesday, May 12, 2026 to 12:00 midnight on Monday, May 18, 2026
- (2) the allocation results telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Wednesday, May 13, 2026, Thursday, May 14, 2026, Friday, May 15, 2026 and Monday, May 18, 2026

H Share certificates in respect of wholly or partially successful applications to be dispatched or deposited into CCASS on or before Tuesday, May 12, 2026

White Form e-Refund payment instructions or refund checks in respect of wholly or partially unsuccessful applications to be dispatched on or before Wednesday, May 13, 2026

Dealings in H Shares on the Stock Exchange to commence at 9:00 a.m. on Wednesday, May 13, 2026

Note:

- (1) All dates and times refer to Hong Kong local dates and times.

SETTLEMENT

Subject to the granting of the listing of, and permission to deal in, the H Shares (including any H Shares which may be issued pursuant to the exercise of the Over-allotment Option) on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the Listing Date or on any other date as determined by HKSCC. Settlement of transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and the HKSCC Operational Procedures in effect from time to time. All necessary arrangements have been made for our H Shares to be admitted into CCASS. Investors should seek the advice of their stockbroker or other professional advisers for details of the settlement arrangements as such arrangements may affect their rights and interests.

APPLICATION CHANNELS

The Hong Kong Public Offering period will begin at 9:00 a.m. on Tuesday, May 5, 2026 and end at 12:00 noon on Friday, May 8, 2026 (Hong Kong time).

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
White Form eIPO service	www.eipo.com.hk	Investors who would like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Tuesday, May 5, 2026 to 11:30 a.m. on Friday, May 8, 2026 (Hong Kong time). The latest time for completing full payment of application monies will be 12:00 noon on Friday, May 8, 2026 (Hong Kong time).
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit electronic application instruction(s) on your behalf through HKSCC's FINI system in accordance with your instructions.	Investors who would not like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian.

The **White Form eIPO** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions, and you are advised not to wait until the last day for applications to apply for Hong Kong Offer Shares.

PUBLICATION OF RESULTS

The Company expects to announce the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on the website of the Stock Exchange at www.hkexnews.hk and our website at www.metistechbio.com by no later than 11:00 p.m. on Tuesday, May 12, 2026 (Hong Kong time).

The results of allocations and identification document numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the time and date and in the manner specified in the section headed "How to Apply for Hong Kong Offer Shares — B. Publication of Results" in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering as set out in the section headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus are not satisfied or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded (subject to application channels), without interest.

No temporary document of title will be issued in respect of the H Shares. No receipt will be issued for sums paid on application. The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time), provided that the Global Offering has become unconditional in all respects and the right of termination described in “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” has not been exercised. Investors who trade H Shares prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Wednesday, May 13, 2026, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, May 13, 2026.

The H Shares will be traded in board lots of 500 H Shares each and the stock code of the H Shares will be 7666.

By order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai

Chairman of the Board, executive Director and chief executive officer

Hong Kong, May 5, 2026

Directors of the Company named in the application to which this announcement relates are: (i) Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; (ii) Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and (iii) Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as proposed independent non-executive Directors.